Investors pump another $8.8M into KC medical device startup, bringing funding total to $20M+ 

March 31, 2020  |  Startland News Staff

A Fairway-based medical device company is getting to the heart of its entrepreneurial journey, securing a fresh $8.8 million in Series A financing, Dr. Nicholas Franano announced Tuesday.

The additional influx to Artio — rebranded from “Metactive” earlier this winter — brings the startup’s total capital raised to more than $20 million. The company has spent years developing groundbreaking, best-in-class products for the peripheral vascular and neurovascular markets, said Franano, founder, president and CEO of Artio.

“We appreciate the strong support from our new and existing investors,” he said. “Our team is looking forward to making our innovative products available to physicians and patients.”

Click here to see why Artio/Metactive was named one of Startland News’ Kansas City Startups to Watch in 2019.

Funds from the latest round are expected to help Artio obtain 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) to market its Solus Gold Embolization Device in the United States.

Solus Gold Embolization Device

The Solus Gold is the first metal implant to provide a solid barrier to blood flow, and is developed for peripheral vascular embolization — a minimally invasive procedure that blocks or reduces blood flow in blood vessels for patients experiencing life-threatening bleeding and other serious medical conditions.

The combination of a low-profile, flexible delivery system and a detachable gold metal implant is designed for passage through tortuous blood vessels, precision placement, and immediate vessel occlusion after placement of a single device, according to the company.

Franano’s team also has revealed two other next-gen embolization products, the Solus Flex device and Aneura system.

Click here to learn more about these peripheral vascular solutions.

“Artio is developing a strong portfolio of disruptive, next-generation peripheral vascular and neurovascular embolization products, and we were thrilled to help lead the latest round of funding,” said Nathaniel Hagedorn, founder and CEO of Northpoint Development. “I have been incredibly fortunate to have so many people help me build my business and am happy to ‘pay it forward’ to a fellow entrepreneur with a clear vision and accomplished team.”

Tagged , , , ,
Featured Business
    Featured Founder
      [adinserter block="4"]

      2020 Startups to Watch

        stats here

        Related Posts on Startland News

        KC among the best cities to find a job

        By Tommy Felts | May 20, 2015

        The City of Fountains is apparently overflowing with job opportunities. Career data Glassdoor recently named Kansas City, Mo. as the No. 2 city to find employment. Kansas City currently has nearly 28,800 employment opportunities, a median base salary $46,000 and median home value of $138,500. Glassdoor determined the final rankings by looking at hiring opportunity…

        Recap: Bill would gut Kansas Bioscience Authority

        By Tommy Felts | May 19, 2015

        A bill in the Kansas legislature if passed would dissolve the Kansas Bioscience Authority, which has recently served as a venture capital organization investing in early-stage bioscience firms. The measure — SB 305 — would shut down the organization and transfer its funds and obligations to the Kansas Department of Commence. Proponents of the KBA say…

        Kansas City named a top tech locale

        By Tommy Felts | May 19, 2015

        Kansas City again was touted as a top tech destination. Tech publication PC Magazine recently named Kansas City as one of “13 high-tech cities you’ll want to call home.” The magazine noted Kansas City’s access to Google Fiber, its low cost of living and communities such as the Kansas City Startup Village as reasons to…

        Flow Forward Medical raises additional $1.3M

        By Tommy Felts | May 18, 2015

        Flow Forward Medical boosted its latest funding round to further develop its device that helps improve outcomes for hemodialysis patients. The Olathe-based company closed a $1.3 million round of additional Series A financing led by the Kansas Bioscience Authority. Flow Forward previously raised $4.4 million, bringing its total funding raised to date to about $5.7 million.…